telaprevir

(redirected from Incivek)
Also found in: Medical.
Related to Incivek: Victrelis
Translations

telaprevir

n telaprevir m
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
Earlier, he was medical director at Vertex and served as a medical lead on the anti-HCV protease inhibitor, telaprevir (INCIVEK), and served as the Vertex Clinical Lead in the Joint Strategic Alliance Team with Janssen Pharmaceutical.
Vertex to end sales of hepatitis C drug Incivek. Reuters Health News.
Telaprevir (Incivek; Son inhibidores En combinacion con Vertex) covalentes de la IFN-PEG y RBV serina proteasa NS3/ Teleprevir: 750mg/ 4A del VHC al tres veces al dia bloquear Boceprevir: estericamente el 800mg/tres veces al clivaje de la dia poliproteina del Simeprevir: virus.
Treatment options for hepatitis C are expanding, with the FDA approving three protease inhibitors in recent years--boceprevir (Victrelis), telaprevir (Incivek), and simeprevir (Olysio)--for treatment of patients with genotype 1 infection.
The previous record for a drug reaching blockbuster status was set in 2011, when hepatitis C therapy Incivek from Vertex Pharmaceuticals raked in $1.56 billion for the entire year.
Over the past several years, the FDA has approved three protease inhibitors, boceprevir (Victrelis), telaprevir (Incivek), and simeprevir (Olysio), for the treatment of patients with genotype 1 infection.
Recently, two HCV NS3/4A protease inhibitors, boceprevir (Victrelis) and telaprevir (Incivek), are approved by the U.S.
Research shows that adding the two new drugs -- Vertex Pharmaceuticals' Incivek and Merck & Co.'s Victrelis -- to the older drug cocktail can boost cure rates to between 65 and 75 percent.
But in recent years, revolutionary advancements have been made in HCV treatment: In 2011, the drugs boceprevir (Victrelis) and telaprevir (Incivek) were approved by the U.S.
In 2011, FDA approved boceprevir (Victrelis, Merck & Co.) and telaprevir (Incivek, Vertex Pharmaceuticals) for treatment ofchronic hepatitis C genotype 1 infection, in combination with pegylated interferon and ribavirin, in adult patients with compensated liver disease.
From 2004 to 2011, the market grew at the CAGR of 2.7%, with the launch of Incivek and Victrelis in 2011 boosting positive growth.